@article{Hradyk_Tsysnetska_2022, title={The Role of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment of Heart Failure in Patients with Type 2 Diabetes Mellitus}, volume={3}, url={https://apmplmi.com/index.php/apmp/article/view/42}, DOI={10.52914/apmp.v3i1.42}, abstractNote={<p>The current data on the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of heart failure in patients with type 2 diabetes mellitus are presented. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for the treatment of diabetes, have been shown to possess a favorable metabolic profile and to significantly reduce atherosclerotic events, hospitalization for heart failure, cardiovascular and total mortality, and progression of chronic kidney disease. Although initially considered to be only glucose-lowering agents, the effects of SGLT2i have expanded far beyond that, and their use is now being studied in the treatment of heart failure and chronic kidney disease, even in patients without diabetes. It is therefore critical for cardiologists, diabetologists, nephrologists, and primary care physicians to be familiar with this drug class.</p>}, number={1}, journal={Actual Problems of Medicine and Pharmacy}, author={Hradyk Тетяна and Tsysnetska Аліна}, year={2022}, month={May}, pages={1–10} }